New chemo delivery method shows promise for tough mesothelioma cases
NCT ID NCT02611037
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new way to deliver chemotherapy directly to the tumor in adults with malignant pleural mesothelioma that cannot be removed by surgery. The treatment, called transarterial chemoperfusion, uses a combination of three drugs (cisplatin, methotrexate, and gemcitabine) to control the disease. The goal was to see if this approach is safe and effective at stopping the cancer from growing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 22612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which palliative care approach boosts quality of life in advanced lung cancer?
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Abdominal chemotherapy after surgery may improve mesothelioma outcomes
- New imaging tracer could spot hidden cancers and fibrosis in one scan
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers